Cargando…
Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
The BCL-2/BCL-X(L) inhibitor navitoclax has shown promise for the treatment of cancer but on-target toxicities have limited its utility. Recently, the generation of selective BCL-2 family inhibitors has enabled a careful dissection of BCL-2 biology, and early work indicates that these molecules have...
Autor principal: | Leverson, Joel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845185/ https://www.ncbi.nlm.nih.gov/pubmed/27308564 http://dx.doi.org/10.1080/23723556.2015.1050155 |
Ejemplares similares
-
HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens
por: Xu, Qing-Wen, et al.
Publicado: (2013) -
Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014) -
Bcl-2: Live and let die
por: Putz, Eva Maria, et al.
Publicado: (2012) -
PNP inhibitors selectively kill cancer cells lacking SAMHD1
por: Davenne, Tamara, et al.
Publicado: (2020) -
Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)